CD274 and endometrial cancer: Monotherapy by PARP inhibitors and PD-1/PD-L1 inhibitors have shown promising results.61 Several phase II trials are currently investigating whether combination therapy of PARP inhibition and PD-1/PD-L1 pathway inhibition are even more effective, as limited data have suggested an added or even synergistic effect.75 The NCT02912572 trial will include 70 patients with metastatic endometrial cancer who have previously been treated with at least one line of chemotherapy.